Amyotrophic Lateral Sclerosis Clinical Trial
Official title:
Confirmation of Self-Reported Incident ALS Cases in the AARP-Diet and Health (AARP-DH) Cohort
Amyotrophic Lateral Sclerosis (ALS) is a rare but rapidly progressive neurological disease
that often results in death within a few years after the diagnosis. The incidence of ALS in
the US is approximately 2.0/100,000/year and is age dependent. Very few epidemiological
studies have investigated the causes of ALS. Last year, Dr. Alberto Ascherio at Harvard
School of Public Health successfully obtained a RO1 grant to investigate the risk of ALS by
documenting ALS cases in five well-established large prospective cohorts: The Nurses' Health
Study (NHS), the Health Professionals Follow-up Study (HPFS), the Cancer Prevention Study II
Nutrition Cohort (CPS IIN), the Multiethnic Cohort (MEC), and the NIH-American Association of
Retired Persons Diet and Health Study (AARP-DH). The primary aims of this grant are to
prospectively clarify the associations between diet and smoking and risk of ALS in this to
date the largest epidemiological study on ALS. Incident ALS cases will be documented via
biennial questionnaires in the first three cohorts. While mortality data will be obtained in
the MEC and AARP-DH cohorts by searching the National Death Index (NDI) Plus, it is also
desirable to identify surviving incident cases in these two cohorts.
The objective of this specific proposal is to ascertain the self-reported incident ALS cases
from the AARP-DH study and obtain consent for medical release following the procedures set up
for Parkinson's disease (PD) cases in the currently approved Parkinson's Genes and
Environment (PAGE) Study IRB approval #06-E-N093. The confirmed ALS cases may be analyzed as
part of the RO1 project. We expect to identify 300 self-reported ALS cases from the AARP
cohort. Detailed analytic plans will be coordinated with Dr. Ascherio.
Amyotrophic Lateral Sclerosis (ALS) is a rare but rapidly progressive neurological disease
that often results in death within a few years after the diagnosis. The incidence of ALS in
the US is approximately 2.0/100,000/year and is age dependent. Very few epidemiological
studies have investigated the causes of ALS. Last year, Dr. Alberto Ascherio at Harvard
School of Public Health successfully obtained a RO1 grant to investigate the risk of ALS by
documenting ALS cases in five well-established large prospective cohorts: The Nurses' Health
Study (NHS), the Health Professionals Follow-up Study (HPFS), the Cancer Prevention Study II
Nutrition Cohort (CPS IIN), the Multiethnic Cohort (MEC), and the NIH-American Association of
Retired Persons Diet and Health Study (AARP-DH). The primary aims of this grant are to
prospectively clarify the associations between diet and smoking and risk of ALS in this to
date the largest epidemiological study on ALS. Incident ALS cases will be documented via
biennial questionnaires in the first three cohorts. While mortality data will be obtained in
the MEC and AARP-DH cohorts by searching the National Death Index (NDI) Plus, it is also
desirable to identify surviving incident cases in these two cohorts.
The objective of this specific proposal is to ascertain the self-reported incident ALS cases
from the AARP-DH study and obtain consent for medical release following the procedures set up
for Parkinson's disease (PD) cases in the currently approved Parkinson's Genes and
Environment (PAGE) Study IRB approval #06-E-N093. The confirmed ALS cases may be analyzed as
part of the RO1 project. We expect to identify 300 self-reported ALS cases from the AARP
cohort. Detailed analytic plans will be coordinated with Dr. Ascherio.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04428775 -
A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease
|
Phase 2 | |
| Recruiting |
NCT04998305 -
TJ-68 Clinical Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) and Muscle Cramps
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05951556 -
Telehealth Implementation of Brain-Computer Interface
|
N/A | |
| Terminated |
NCT04579666 -
MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2 | |
| Recruiting |
NCT04082832 -
CuATSM Compared With Placebo for Treatment of ALS/MND
|
Phase 2/Phase 3 | |
| Completed |
NCT01925196 -
Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation
|
||
| Completed |
NCT02496767 -
Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year
|
Phase 3 | |
| Recruiting |
NCT04816227 -
Expression Profile Study of Macrophages From Patients Affected by ALS or Other Related Motor Impairments
|
||
| Active, not recruiting |
NCT04494256 -
A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation
|
Phase 1/Phase 2 | |
| Completed |
NCT03706391 -
Study of ALS Reversals 4: LifeTime Exposures
|
||
| Recruiting |
NCT04882904 -
Continuous Measurement of Activity in Patients With Muscle Pathology and in Control Subjects. ActiSLA Part.
|
N/A | |
| Completed |
NCT04557410 -
Open Label Study: Treatment of ALS Fatigue With PolyMVA
|
Phase 1 | |
| Active, not recruiting |
NCT04948645 -
A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Sclerosis
|
Phase 1 | |
| Not yet recruiting |
NCT04089696 -
Validation of the "ExSpiron©" in Patients With ALS
|
N/A | |
| Not yet recruiting |
NCT04220190 -
RAPA-501 Therapy for ALS
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT05860244 -
Effect of Salbutamol on Walking Capacity in Ambulatory ALS Patients
|
Phase 2 | |
| Not yet recruiting |
NCT06450691 -
Modeling Amyotrophic Lateral Sclerosis With Fibroblasts
|
N/A | |
| Recruiting |
NCT02917681 -
Study of Two Intrathecal Doses of Autologous Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03067857 -
Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02874209 -
Noninvasive Assessment of Neuronal Damage by MRI Sodium ( 23Na ) in Amyotrophic Lateral Sclerosis
|
N/A |